In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public health threat. This article reviews their mechanisms of resistance, epidemiology, and clinical impact and current and upcoming therapeutic options. In vitro and in vivo treatment studies and pharmacokinetic and pharmacodynamic (PK/PD) models are discussed.

Excessive systemic inflammation and raised IL-6 levels resulting from dysregulated host immune responses^1-3 are associated with adverse clinical outcomes in patients hospitalized with COVID-19.⁴ This led to the design of several randomized clinical trials assessing the efficacy of IL-6 antagonists in patients with COVID-19. The IL-6 antagonists commonly investigated were monoclonal antibodies that bind either to membrane-bound and soluble IL-6 receptors (eg, tocilizumab and sarilumab) or directly to IL-6 (eg, siltuximab).⁵

Background. Several series predicting the prognosis of staphylococcal prosthetic joint infection (PJI) managed with debridement, antibiotics, and implant retention (DAIR) have been published, but some of their conclusions are controversial. At present, little is known regarding the efficacy of the different antibiotics that are used or their ability to eliminate methicillin-resistant S. aureus (MRSA) infection. Methods. This was a retrospective, multicenter, observational study of cases of PJI by S. aureus that were managed with DAIR (2003–2010). Cases were classified as failures when infection persistence/relapse, death, need for salvage therapy, or prosthesis removal occurred. The parameters that predicted failure were analyzed with logistic and Cox regression. Results. Out of 345 episodes (41% men, 73 years), 81 episodes were caused by MRSA. Fifty-two were hematogenous, with poorer prognoses, and 88% were caused by methicillin-susceptible S. aureus (MSSA). Antibiotics were used for a median of 93 days, with similar use of rifampin-based combinations in MSSA- and MRSA-PJI. Failure occurred in 45% of episodes, often early after debridement. The median survival time was 1257 days. There were no overall prognostic differences between MSSA- and MRSA-PJI, but there was a higher incidence of MRSA-PJI treatment failure during the period of treatment (HR 2.34), while there was a higher incidence of MSSA-PJI treatment failure after therapy. Rifampin-based combinations exhibited an independent protective effect. Other independent predictors of outcome were polymicrobial, inflammatory, and bacteremic infections requiring more than 1 debridement, immunosuppressive therapy, and the exchange of removable components of the prosthesis. Conclusions. This is the largest series of PJI by S. aureus managed with DAIR reported to date. The success rate was 55%. The use of rifampin may have contributed to homogenizing MSSA and MRSA prognoses, although the specific rifampin combinations may have had different efficacies.

Read the full review for this F1000Prime recommended article: Health care-associated native valve endocarditis: importance of non-nosocomial acquisition.

Prosthetic joint infection (PJI) is an uncommon complication (1–2%) of joint replacement surgery associated with high morbidity and medical expenditure [ 1 x 1 Huo, MH, Gilbert, NF, and Parvizi, J. What's new in total hip arthroplasty. J Bone Joint Surg Am. 2007; 89: 1874–1885 Crossref | PubMed | Scopus (22) | Google Scholar See all References , 2 x 2 Zimmerli, W, Trampuz, A, and Ochsner, PE. Prosthetic‐joint infections. N Engl J Med. 2004; 351: 1645–1654 Crossref | PubMed | Scopus (627) | Google Scholar See all References ]. The most frequently isolated microorganisms are gram-positive cocci. However, gram-negative bacteria (GNB) constitute 10–23% of all episodes, and these infections are often acute [ 3 x 3 Hsieh, PH, Lee, MS, Hsu, KY, Chang, YH, Shih, HN, and Ueng, SW. Gram‐negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis. 2009; 49: 1036–1043 Crossref | PubMed | Scopus (92) | Google Scholar See all References , 4 x 4 Tattevin, P, Cremieux, AC, Pottier, P, Huten, D, and Carbon, C. Prosthetic joint infection: when can prosthesis salvage be considered?. Clin Infect Dis. 1999; 29: 292–295 Crossref | PubMed | Scopus (172) | Google Scholar See all References , 5 x 5 Zimmerli, W and Ochsner, PE. Management of infection associated with prosthetic joints. Infection. 2003; 31: 99–108 Crossref | PubMed | Scopus (237) | Google Scholar See all References ].